Media Thread, page-10685

Thanks for posting this, GMT2.

Well - that was a super confident Leslie. She clearly expects great things from Azer-Cel - which is entirely reasonable given the results of the Phase 1 trial - but her eyes really light up when it comes to CF33. And that's understandable too - given the early data from the MAST trial, and the enormous breadth of the potential application across many/most solid tumour types, both in the Vaxinia form and through OnCARlytics.

"We will continue, hopefully, to get great news off of the MAST study ..."

"I have to say that the oncolytic viral therapies, as well as Azer-Cel, are... are behaving ...quite nicely."

Cheers

Dave